Výsledky vyhledávání - "C. Angerstein"

[(68)Ga-labeled peptides for clinical trials - production according to the German Drug Act: the Göttingen experience]

Autor: Birgit, Meller, C, Angerstein, T, Liersch, M, Ghadimi, C-O, Sahlmann, J, Meller

Publikováno v: Nuklearmedizin. Nuclear medicine. 51(2)

The AMG implies far-reaching implications for the synthesis of new radiopharmaceuticals for clinical trials.As a part of the DFG-funded Clinical Research Group (KFO 179) a project designated "Immuno-PET for assessment of early response to radiochemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::faf7d215a717316d81b330430dbeb0c3
https://pubmed.ncbi.nlm.nih.gov/22249368

Zobrazit plný text záznamu

[Clinical evaluation of a new thyroglobulin immunoradiometric assay in the follow-up of differentiated thyroid carcinoma]

Autor: C-O, Sahlmann, I, Schreivogel, C, Angerstein, U, Siefker, K, Lehmann, G, Altenvoerde, M, Hüfner, J, Meller

Publikováno v: Nuklearmedizin. Nuclear medicine. 42(2)

Formal and clinical comparison of a new 3 (rd) -generation-Tg-IRMA (3-G-IRMA; Dynotest Tg-plus) with a conventional Tg-IRMA (3-G-IRMA; SELco Tg-assay) for patients with differentiated thyroid carcinoma. In addition we evaluated, if thyroglobulin (Tg)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b4154b05f7af08e53b647f012c3acb1
https://pubmed.ncbi.nlm.nih.gov/12695789

Zobrazit plný text záznamu

(99m)Tc-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model

Autor: Wolfgang Becker, C. Angerstein, T. O'Reilly, E. Kunze, H.L. Schulz, F. Kauer, S. Gratz, K. Nebendahl, T. M. Behr, H. Eiffert, Otto C. Boerman, Martin Béhé

Publikováno v: Nuclear Medicine Communications, 22, 9, pp. 1003-13
Nuclear Medicine Communications, 22, 1003-13

Item does not contain fulltext INTRODUCTION: In the present study, (99m)Tc-radiolabelled E-selectin binding peptide ((99m)Tc-IMP-178) was investigated for its potential to image acute pyogenic osteomyelitis in a new animal model. Intraindividual comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c16d5361c276d6e2105085fe2744d49
https://doi.org/10.1097/00006231-200109000-00010

Zobrazit plný text záznamu

Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential

Autor: T M, Behr, M, Béhé, C, Angerstein, S, Gratz, R, Mach, L, Hagemann, N, Jenner, M, Stiehler, K, Frank-Raue, F, Raue, W, Becker

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5

The high sensitivity of pentagastrin stimulation in detecting primary or metastatic medullary thyroid cancer (MTC) suggests widespread expression of the corresponding receptor type on human MTC. Indeed, autoradiographic studies demonstrated cholecyst

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fb060f7be3db7f77f3c957aedae36e08
https://pubmed.ncbi.nlm.nih.gov/10541353

Zobrazit plný text záznamu

Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters

Autor: T M, Behr, G, Sgouros, M G, Stabin, M, Béhé, C, Angerstein, R D, Blumenthal, C, Apostolidis, R, Molinet, R M, Sharkey, L, Koch, D M, Goldenberg, W, Becker

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5

Usually, the red marrow (RM) is the first dose-limiting organ in radioimmunotherapy. However, several studies have obtained only poor correlations between the marrow doses and the resulting toxicities. Furthermore, RM doses are mostly not determined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c171ee888c56344ada50676a58580b56
https://pubmed.ncbi.nlm.nih.gov/10541340

Zobrazit plný text záznamu

Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study

Autor: T M, Behr, A L, Salib, T, Liersch, M, Béhé, C, Angerstein, R D, Blumenthal, A, Fayyazi, R M, Sharkey, B, Ringe, H, Becker, B, Wörmann, W, Hiddemann, D M, Goldenberg, W, Becker

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5

At the time of surgery, occult metastases (micrometastases) are present in more than 50% of colorectal cancer patients, and the liver is the most frequent site of apparent metastatic disease. Frequently, adjuvant chemotherapy is unable to prevent tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2d4cda7543f19d67b59dd55675601652
https://pubmed.ncbi.nlm.nih.gov/10541369

Zobrazit plný text záznamu

Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors

Autor: T M, Behr, N, Jenner, M, Béhé, C, Angerstein, S, Gratz, F, Raue, W, Becker

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7bd1c858fd15e24a442f2113915bcbea
https://pubmed.ncbi.nlm.nih.gov/10452322

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání